Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07490288 | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | recruiting | N/A | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751588 | Plasma ctDNA Monitoring in Pediatric Acute Leukemia | not yet recruiting | — | 25 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 |
| NCT07751991 | A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML | recruiting | Phase 1 | 40 | Charm TherapeuticsINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752121 | First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms(LUNIS) | not yet recruiting | — | 190 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02861417 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 204 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03253848 | Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia | active not recruiting | N/A | 202 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT03316573 | Pembrolizumab in Neoplasms or Lymphomas | suspended | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04994808 | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia | terminated | Phase 2 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05028621 | Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease | suspended | N/A | 135 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06456463 | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy(TRILLIUM) | active not recruiting | Phase 2 | 85 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06609928 | FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07008118 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 120 | Incyte CorporationINDUSTRY | 5 | Aug 6, 2026 | clinicaltrials |
| NCT07425782 | Venetoclax Combined With Azacitidine for Consolidation Therapy in AML | recruiting | Phase 2 | 216 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07670130 | Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis(ND-AML) | recruiting | — | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07672262 | VA Consolidation in Intermediate-Risk AML | recruiting | Phase 2 | 226 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07743047 | Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality(SynT) | not yet recruiting | — | 65 | IRCCS San RaffaeleOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07744724 | Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL | not yet recruiting | Phase 2 | 48 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744737 | Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL | not yet recruiting | Phase 2 | 34 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744750 | Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749365 | Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | recruiting | Phase 2 | 53 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT04281199 | TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06006403 | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | completed | Phase 1 / Phase 2 | 5 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06641648 | A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. | recruiting | Phase 1 | 12 | Peking University First HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | recruiting | Phase 2 / Phase 3 | 312 | Moleculin Biotech, Inc.INDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06895538 | Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy | recruiting | Phase 2 / Phase 3 | 24 | Peking University First HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07740603 | Study of CD38 and CD56 in Chronic Myeloid Leukemia | not yet recruiting | — | 200 | Sohag UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07748455 | HMA-Venetoclax Induction in Newly Diagnosed AML(VENTURE-AML) | not yet recruiting | Phase 2 | 60 | Pakistan Blood and Marrow Transplant (PBMT) GroupOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02971397 | Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | recruiting | Phase 1 | 24 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06960993 | Mosaic Trial for Stem Cell Transplant Recipients(Mosaic) | recruiting | N/A | 356 | Northwestern UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07743112 | A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 2 | 43 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT01343173 | Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib(STIM 2) | completed | N/A | 220 | University Hospital, BordeauxOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06290765 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera(PV) | withdrawn | Phase 4 | 0 | PharmaEssentiaINDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT06985147 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | active not recruiting | Phase 2 | 60 | Disc Medicine, IncINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07679334 | Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms | not yet recruiting | Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04975919 | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05457556 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | active not recruiting | Phase 3 | 66 | Children's Oncology GroupNETWORK | 3 | Jul 30, 2026 | clinicaltrials |
| NCT06021600 | A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07548710 | Study of SA+X in the Treatment of Newly Diagnosed AML | recruiting | Phase 2 | 205 | Ruijin HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07737769 | Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06034470 | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | active not recruiting | Phase 1 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734272 | Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative(STANDARDIZE-PV) | not yet recruiting | N/A | 32 | Massachusetts General HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | not yet recruiting | Phase 3 | 168 | Ruijin HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2026source: clinicaltrials